The remaining 25.8% focused on Triple Negative Breast Cancer (TNBC) samples or involved Luminal A (5.0%), Luminal B (1.7%) and HER2-positive (1.7%) breast cancer samples. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.